Compare Pfizer Inc (PFE) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Zoom Video Communications, Inc. — how do they compare? Pfizer Inc trades at $27.9 (market cap $158.56B), while Zoom Video Communications, Inc. trades at $95.95 (market cap $27.62B). The key difference: Pfizer Inc is far larger — about 5.7× Zoom Video Communications, Inc.'s market cap, and Pfizer Inc pays a 6.18% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Zoom Video Communications, Inc. for 92 Days on average.
| PFE | ZM | |
|---|---|---|
Market Cap | $158.56B | $27.62B |
Volume | 44,138,282 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $29.02 | $111.88 |
52-Week Low | $23.67 | $72.72 |
Typical Hold Time | 158 Days | 92 Days |
Enterprise Value | $210.06B | $20.43B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Zoom Communications (ZM) trades at $94.77, up 0.61% with a bullish technical outlook. The stock shows strong profitability with 77.3% gross margins and 65.19% net income margin, supported by recent earnings beats. Analyst consensus targets $118.08 with 38.8% buy ratings. Recent AI product launches and board appointments signal strategic growth initiatives.
Zoom presents a compelling investment case with attractive valuation (P/E 8.79) and robust profitability, though near-term risks include competitive pressures and reliance on international sales. The stock's proximity to resistance at $95 requires monitoring, but institutional interest and AI-driven revenue initiatives support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
